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ABSTRACT 
Lysergic acid diethylamide (LSD) is a serotonin 5-hydroxytryptamine-2A (5-HT2A) receptor 
agonist that is used recreationally worldwide. Interest in LSD research in humans waned after 
the 1970s, but the use of LSD in psychiatric research and practice has recently gained 
increasing attention. LSD produces pronounced acute psychedelic effects, but its influence on 
plasma steroid levels over time have not yet been characterized in humans. The effects of LSD 
(200µg) or placebo on plasma steroid levels were investigated in 16 healthy subjects using a 
randomized, double-blind, placebo-controlled cross-over study design. Plasma concentration-
time profiles were determined for 15 steroids using liquid-chromatography tandem mass-
spectrometry. LSD increased plasma concentrations of the glucocorticoids cortisol, cortisone, 
corticosterone, and 11-dehydrocorticosterone compared with placebo. The mean maximum 
concentration of LSD was reached at 1.7h. Mean peak psychedelic effects were reached at 
2.4h, with significant alterations in mental state from 0.5h to >10h. Mean maximal 
concentrations of cortisol and corticosterone were reached at 2.5h and 1.9h, and significant 
elevations were observed 1.5-6h and 1-3h after drug administration, respectively. LSD also 
significantly increased plasma concentrations of the androgen dehydroepiandrosterone but not 
other androgens, progestogens, or mineralocorticoids compared with placebo. A close 
relationship was found between plasma LSD concentrations and changes in plasma cortisol and 
corticosterone and the psychotropic response to LSD, and no clockwise hysteresis was 
observed. In conclusion, LSD produces significant acute effects on circulating steroids, 
especially glucocorticoids. LSD-induced changes in circulating glucocorticoids were associated 
with plasma LSD concentrations over time and showed no acute pharmacological tolerance. 
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INTRODUCTION 
 Lysergic acid diethylamide (LSD) was discovered in 1943 and is the prototypic 
serotonergic hallucinogen (1, 2). LSD was used in psychiatric research in the 1950s to 1970s to 
study psychotic-like states (i.e., model psychosis) and as an adjunct to psychotherapy (1) before 
its widespread recreational use. Today, LSD is still frequently used for personal and spiritual 
purposes. Additionally, renewed interest has been seen in the use of LSD in psychiatric 
research (3) and practice (4). Pharmacologically, LSD mainly acts as an agonist at serotonin 5-
hydroxytryptamine-1 (5-HT1) and 5-HT2 receptors, but it also interacts with dopamine D1, D2, 
and D3 receptors and adrenergic α1 receptors (2). In contrast to such stimulants as 
amphetamines or cocaine, LSD does not interact with monoamine transporters (2). In humans, 
LSD induces alterations in perception, methylenedioxymethamphetamine (MDMA)-like 
empathogenic mood effects, and moderate sympathomimetic stimulation (3).   
Many psychoactive substances activate the hypothalamic-pituitary-adrenal (HPA) axis, 
leading to the release of adrenocorticotropic hormone (ACTH) and glucocorticoids (5, 6). 
However, limited data have been reported on the effects of LSD on the HPA axis. In rats, LSD 
increased 17-hydroxy-ketosteroid and 17-ketosteroid levels in urine, consistent with HPA axis 
activation (7), but effects on circulating corticosterone could not be shown (8). LSD was 
reported to increase cortisol levels in zebrafish (9). Early studies in humans found that LSD 
increased 17-ketosteroid excretion in urine (10, 11), but effects on circulating steroid levels were 
not investigated. LSD also blunted the normal increase in 17-ketosteroid after ACTH 
administration (10). We recently found that LSD significantly increased plasma cortisol 180 min 
after LSD administration in humans (3), also consistent with HPA axis activation. However, a 
more comprehensive analysis of the effects of LSD on circulating levels of different steroids and 
its time course is still missing. 
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Corticosteroids, androgens, and progestogens may all contribute to or modulate 
psychotropic drug actions (12, 13). For example, amphetamine or MDMA-induced increases in 
plasma cortisol levels were associated with subjective drug effects (14, 15), and stress-induced 
increases in plasma cortisol levels correlated with euphoric responses to amphetamine (16). 
Testosterone plays a role in social behavior (17) that is enhanced by MDMA (18). Testosterone 
and progesterone both reduced cocaine self-administration in female rhesus monkeys (19), and 
progesterone is known to be associated with reductions of subjective responses to and the use 
of psychostimulants in women (13, 20, 21). Plasma dehydroepiandrosterone (DHEA) levels 
correlated with the subjective response to MDMA (14). Increases in DHEA and progesterone 
were also observed after γ-hydroxybutyrate administration (22).  
Glucocorticoids are involved in the stress response and the modulation of behavior. In 
humans, inactive cortisone and active cortisol are the main glucocorticoids (23). Inactive 11-
dehydrocorticostrone and active corticosterone (i.e., the major glucocorticoids in rodents) are 
present at lower concentrations than cortisone and cortisol in human plasma. However, 
corticosterone, which also has additional mineralocorticoid properties, presents a higher 
brain/plasma concentration ratio than cortisol (24). Mineralocorticoids are involved in the 
regulation of sodium absorption and blood pressure (25), and they also play a role in modulating 
the immune response (26). 11-Deoxycortisol is a precursor of cortisol (27). Aldosterone is the 
most important mineralocorticoid. 11-Deoxycorticosterone is a precursor of corticosterone and 
aldosterone and has mineralocorticoid activity (28).  
To characterize the influence of LSD on plasma steroid levels, we evaluated the acute 
effects of LSD on the plasma concentrations of a series of steroids over 24 h in healthy 
subjects. We also explored the effects of LSD on a wide range of other steroids. The plasma 
LSD concentration-steroid effect response curves over time were also plotted and compared 
with the LSD exposure-psychotropic effect relationship. 
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MATERIALS AND METHODS 
Study design 
 The study used a double-blind, placebo-controlled, cross-over design with two 
experimental test sessions in balanced order. The washout periods between sessions were at 
least 7 days. The study was conducted in accordance with the Declaration of Helsinki and 
International Conference on Harmonization Guidelines in Good Clinical Practice and approved 
by the Ethics Committee of the Canton of Basel, Switzerland, and Swiss Agency for Therapeutic 
Products (Swissmedic). The administration of LSD to healthy subjects was authorized by the 
Swiss Federal Office for Public Health, Bern, Switzerland. The study was registered at 
ClinicalTrials.gov (NCT01878942). All of the subjects provided written informed consent after 
being given written and oral descriptions of the study, the procedures involved, and the effects 
and possible risks of LSD administration. 
 
Participants 
 Sixteen healthy subjects (eight men and eight women; mean age ± SD: 28.6 ± 6.2 years; 
range: 25-51 years) were included. The exclusion criteria were pregnancy, personal or family 
(first-degree relative) history of psychotic or major affective disorder, regular use of medications, 
chronic or acute physical illness, lifetime prevalence of illicit drug use > 10 times (except for 
tetrahydrocannabinol), illicit drug use within the last 2 months, and illicit drug use during the 
study as reported in detail elsewhere (3). The subjects were asked to abstain from excessive 
alcohol consumption between test sessions and particularly limit their use to one drink on the 
day before the test sessions. Additionally, the participants were not allowed to drink caffeine-
containing liquids after midnight before the study day. Three subjects were light smokers (< 10 
cigarettes/day) and were told to maintain their usual smoking habits but not smoke during the 
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sessions. We performed urine drug tests at screening and before each test session using 
TRIAGE 8 (Biosite, San Diego, CA, USA). The safety recommendations for high-dose 
hallucinogen research were followed (29). 
 
Study procedures 
 The test sessions began at 8:00 AM. A urine sample was taken to verify abstinence from 
drugs of abuse, and a pregnancy test was performed in women. An indwelling intravenous 
catheter was placed in an antecubital vein for blood sampling, and the subjects completed 
baseline measurements. A single dose of LSD (200 µg) or placebo was administered orally at 
9:00 AM. A standardized lunch and dinner were served at 1:30 PM and 5:30 PM, respectively. 
The subjects were sent home the next day at 9:30 AM after the 24 h blood sample collection. 
The sessions were conducted in a calm laboratory environment. The subjects did not engage in 
any physical activity and were resting in hospital beds during the test session. Blood samples 
for the analysis of plasma steroid hormone levels were collected in lithium heparin tubes 1 h 
before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 24 h after LSD or placebo administration. Blood 
samples were immediately centrifuged, and plasma was rapidly stored at -20°C. Plasma LSD 
concentrations were determined using liquid-chromatography tandem mass-spectrometry (LC-
MS/MS; (30). The pharmacokinetics of LSD have been reported previously (31), and LSD 
concentrations are included herein to describe the LSD exposure-steroid response effect 
relationship. The subjective and autonomic effects of LSD were also recorded in this study and 
have been reported previously (3). The subjective effects of LSD over time were repeatedly 
recorded at the times of blood sampling using visual analog scales (VAS) as previously reported 
(3, 31) and are also presented herein for comparisons with the effects of LSD on steroid 
concentrations (Fig. 3 and Fig. S1). VASs included “any drug effects”, “good drug effects”, “bad 
drug effects”, “fear”, and “stimulation”. VASs were presented as 100-mm horizontal lines (0-
100%) marked “not at all” on the left and “extremely” on the right (3, 32).  
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Steroid quantification 
 Plasma steroid hormone levels (cortisol, cortisone, corticosterone, 11-
dehydrocorticosterone, 11-deoxycorticosterone, aldosterone, DHEA, DHEA sulfate [DHEAS], 
∆4-androstene-3,17-dione [androstenedione], testosterone, 11-deoxycortisol, progesterone, 5α-
dihydrotestosterone, androsterone, and 17α-hydroxyprogesterone) were determined as 
previously described with minor adaptations (6). A detailed description of the materials, 
procedure, and method validation is included in the Supplemental Data. 
Briefly, for solid-phase extraction, 700 µl of each plasma sample was mixed with 100 µl 
of protein precipitation solution (0.8 M zinc sulfate in water/methanol [50/50, v/v]) that contained 
deuterium-labeled aldosterone, corticosterone, androstenedione, androsterone, 5α-
dihydrotestosterone, and testosterone as internal standards and diluted to a final volume of 1 ml 
with water. The samples were incubated in a thermoshaker for 10 min at 4°C with thorough 
shaking (1300 rotations per minute). The samples were then centrifuged for 10 min at 16,000 × 
relative centrifugal force at 4°C, and 700 µl of the supernatants was transferred to Oasis HBL 
SPE cartridges, preconditioned with methanol and water. After washing once with 1 ml of water 
and twice with 1 ml of methanol/water (10/90, v/v), the steroids were eluted with 1 ml of 
methanol and evaporated to dryness. The samples were then reconstituted in 25 µl of methanol. 
The steroids were separated and quantified by ultra-pressure LC-MS/MS (UPLC-MS/MS) using 
an Agilent 1290 UPLC coupled to an Agilent 6490 triple quadrupole mass spectrometer 
equipped with a jet-stream electrospray ionization interface. Analyte separation was achieved 
using a reverse-phase column (Waters ACQUITY UPLC BEH C18, 1.7 µm, 2.1 × 150 mm). 
Mass Hunter software (Agilent Technologies) was used for data acquisition and analysis. As 
described in detail in the supplement, the variation coefficient was <15% and accuracy between 
85 and 115% tested at three concentrations for all analytes. The recovery of control samples 
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was in the range of 80-120%.  
 
 
Drugs 
 Gelatin capsules that contained 100 µg LSD (D-lysergic acid diethylamide hydrate; 
Lipomed AG, Arlesheim, Switzerland) and corresponding placebo capsules were prepared with 
authorization from the Swiss Federal Office for Public Health. LSD was administered in a single 
absolute dose of 200 µg, corresponding to a dose of 2.8 ± 0.1 mg/kg body weight (mean ± 
SEM). The same dose was previously used in LSD-assisted psychotherapy in a clinical study 
(4). The dose was in the upper range of doses that are taken for recreational purposes and 
expected to induce robust effects in humans (1). 
 
Statistical analyses 
 To determine differences between LSD and placebo, maximum concentration (Cmax) 
values and areas under the concentration-time curve (AUCs) were compared for each steroid 
using repeated-measures analysis of variance (ANOVA), with drug (LSD vs. placebo) as the 
within-subject factor. Gender differences were determined by including gender (male vs. female) 
as a between-subject factor in the ANOVA. To test how long the subjective, cortisol, and 
corticosterone responses last over time, data were also analyzed using two-way ANOVAs with 
drug and time as factors and Tukey tests were used for post hoc comparisons between 
corresponding time points. Cmax was determined directly from the concentration-time curves. 
AUC values were determined from time 0.5 h to 10 h (AUC10) using the trapezoidal method. The 
LSD exposure-steroid concentration response relationships were explored by plotting the LSD 
response as a function of steroid concentration after LSD administration minus the individual 
time-matched concentration after placebo as a function of LSD plasma concentrations at each 
time point (hysteresis curves). Correlations between mean LSD concentrations and mean LSD-
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induced subjective (5 scales) or endocrine responses (cortisol and corticosterone) over time as 
well as correlations between subjective and endocrine responses over time (n=12 time points) 
within the 16 subjects were then analyzed using Spearman’s rank correlations. The level of 
significance was set to P < 0.05. Seventeen correlations were tested, giving a Bonferroni-
corrected statistical threshold of P<0.003. The statistical analyses were performed using 
STATISTICA 12 software (StatSoft, Tulsa, OK, USA). 
 
RESULTS 
 The plasma concentration-time curves of the different steroid hormones after LSD and 
placebo administration are shown in Fig. 1 and 2. Peak steroid concentrations, total steroid 
exposure over time (AUC10 values), and statistics are presented in Table 1. LSD significantly 
increased the plasma concentrations of the glucocorticoids cortisol, cortisone, corticosterone, 
and 11-dehydrocorticosterone compared with placebo (Fig. 1B-E). LSD also significantly 
increased the sums of cortisol+cortisone and corticosterone+11-dehydrocorticosterone and the 
cortisol/cortisone and corticosterone/11-dehydrocorticosterone ratios (Table 1), indicating 
elevated glucocorticoid production. LSD had no effect on plasma concentrations of the cortisol 
precursor 11-deoxycortisol (Fig. 1A), the mineralocorticoid aldosterone (Fig. 1G), or the 
moderate mineralocorticoid 11-deoxycorticosteone (Fig. 1F). LSD significantly increased plasma 
concentrations of DHEA compared with placebo (Fig. 2A) and also increased the plasma 
exposure (AUC10 but not Cmax) of androstenedione compared with placebo (Fig. 2C). In contrast, 
LSD did not alter plasma concentrations of the androgens DHEAS (Fig. 2B), testosterone (Fig. 
2D, F), 5α-dihydrotestosterone, or androsterone (Table 1). Similarly, LSD had no effect on 
plasma concentrations of the progestogens progesterone (Fig. 2G) and 17α-
hydroxyprogesterone (Fig. 2E). As expected, testosterone levels were higher in men than in 
women, but no sex differences in testosterone levels in response to LSD were found compared 
with placebo. Similarly, no other drug and gender interaction effects on any of the steroid levels 
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were observed. 
LSD exposure-steroid concentration response relationships are shown in Fig. 3. 
Pharmacokinetic data on LSD from the present study have been published elsewhere in detail 
(31). The Cmax of LSD was reached 1.7 ± 1 h (mean ± SD) after LSD administration (Fig. 3A, B). 
The peak psychotropic effect was reached 2.4 ± 0.8 h, with significant alterations in mental state 
from 0.5 to 10 h after LSD administration (Fig. 3A, B). Maximum concentrations of cortisol (Fig. 
3C, D) and corticosterone (Fig. 3E, F) were reached at 2.5 ± 0.8 h and 1.9 ± 0.5 h (mean ± SD), 
and significant elevations were observed 1.5-6 h and 1-3 h after LSD administration, 
respectively. Thus, plasma levels of corticosterone increased more rapidly and fell more rapidly 
back to baseline levels compared with cortisol levels (Fig. 3E, F). Counterclockwise hysteresis 
was observed for subjective “any drug effects” and cortisol, consistent with an initial delay 
between increases in plasma LSD concentration and drug effects that was attributable to drug 
absorption/distribution up to 2.5 h (Fig. 3B, D). After maximal drug effects were reached at 2.5 
h, the psychotropic effects and changes in plasma cortisol levels decreased slowly, paralleling 
the steady decrease in the plasma levels of LSD (Fig. 3A, C) and presenting a close 
concentration-effect relationship up to 24 h (Fig. 3B, D). The average plasma level of LSD was 
strongly correlated with the average subjective “any drug effects” and the average level of 
cortisol over time (Rs=0.94, P<0.001 and Rs=0.97, P<0.001, respectively). The relationship 
between subjective “any drug effects” and circulating glucocorticoids was explored by plotting 
the LSD-induced subjective “any drug effects” as a function of changes in the plasma 
concentrations of cortisol and corticosterone (Fig. 3G, H). After LSD administration, subjective 
drug effects increased together with plasma corticosterone levels but more rapidly than plasma 
cortisol levels. At 1 h after LSD administration, 80% of the average maximal subjective drug 
effect was reached, with more than 50% of the maximal corticosterone response but less than 
50% of the maximal cortisol response. Thus, the psychotropic effects of LSD seemed to appear 
faster than the LSD-induced changes in plasma cortisol levels. Nevertheless, the average 
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subjective “any drug effect” was closely related to the levels of cortisol and corticosterone 
(Rs=0.97, P<0.001 and Rs=0.90, P<0.001, respectively). LSD produced pronounced subjective 
“good drug effects” and “stimulation”, but induced only small increases in subjective “bad drug 
effects” and “fear” compared with placebo as reported previously (3). Average subjective “good 
drug effects” and “stimulation” were both strongly associated with the plasma levels of LSD over 
time (Rs=0.88, P<0.001 and Rs=0.84, P<0.001, respectively). Average “good drug effects” and 
“stimulation” were both also associated with the plasma levels of cortisol (Rs=0.93, P<0.001 and 
Rs=0.82, P<0.001, respectively) and corticosterone (Rs=0.86, P<0.001 and Rs=0.84, P<0.001, 
respectively). In contrast, LSD-induced “bad drug effects” or “fear” did not correlate with LSD-
induced increases in cortisol or corticosterone over time. Supplemental Fig. S1 shows the 
concentration-effect curves of MDMA (125 mg) for “any drug effects”, cortisol, and 
corticosterone based on our previous study in 16 healthy subjects (6, 33) for comparisons with 
the concentration-effect curves of LSD (Fig. 3B, D, F). The MDMA concentration-effect 
relationships for the psychotropic effects and glucocorticoid responses exhibited clockwise 
hysteresis, indicating acute pharmacological tolerance (Supplemental Fig. S1A-C). Consistently, 
the average subjective “any drug effects” did not significantly correlate with the average plasma 
levels of MDMA over time. After MDMA administration, the subjective drug effects increased 
faster and particularly decreased faster than the plasma levels of cortisol (Supplemental Fig. 
S1D) and corticosterone (Supplemental Fig. S1E; i.e., clockwise hysteresis). Thus, MDMA-
induced changes in plasma glucocorticoid levels over time did not well reflect the psychotropic 
effects of the drug, in contrast to LSD, in which no tolerance was observed. 
 
DISCUSSION 
 The present study provided insights into the acute effects of LSD on the plasma levels of 
a series of steroids in healthy humans. LSD increased circulating glucocorticoid levels, whereby 
the levels of both inactive 11-dehydrocorticosterone and cortisone and active corticosterone and 
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cortisol were elevated compared with placebo, indicating HPA axis stimulation. The LSD-
induced changes in circulating cortisol and corticosterone had, in contrast to the glucocorticoid 
response to MDMA, a close relationship with both the plasma concentrations of LSD and 
psychotropic response to LSD. No clockwise hysteresis in the LSD concentration-effect plots 
was observed, thus indicating no acute tolerance to the effects of LSD on glucocorticoid 
concentrations or subjective drug effects, in contrast to the pronounced acute tolerance 
observed with MDMA. LSD also significantly increased plasma concentrations of the androgens 
DHEA (AUC10, Cmax) and androstenedione (AUC10), but the concentration of testosterone was 
unaltered, and the ratio of active to inactive androgens (testosterone/androstenedione) 
decreased. Other androgens, as well as progestogens and mineralocorticoids, were unaffected 
by LSD. 
The LSD-induced relative increase in corticosterone was greater than the increase in 
cortisol. The brain penetration of corticosterone is greater compared with cortisol because of 
differential transport by P-glycoprotein at the blood-brain barrier (24). Thus, the effect of LSD on 
brain corticosterone concentrations may be more prominent. Additionally, the LSD-induced 
changes in circulating corticosterone in the present study also more closely reflected 
psychotropic alterations over time, in which plasma cortisol levels increased later in time than 
the subjective effects of LSD after drug administration. 
Stimulation of the HPA axis by LSD has previously been demonstrated in animals (7, 9) and 
humans (10). The present study in humans provided a more comprehensive analysis of plasma 
concentration-over-time profiles of a series of different steroids. LSD is a prototypic serotonergic 
hallucinogen that mainly acts as a potent serotonin 5-HT1 and 5-HT2 receptor agonist. It also 
binds to dopamine D1-3 and adrenergic α1 receptors but does not inhibit monoamine transporters 
(2, 34). The LSD-induced increase in circulating glucocorticoids suggests a role for serotonin 
and 5-HT1 and 5-HT2 receptors in HPA axis stimulation. In the present study, LSD also 
increased plasma levels of prolactin (3), which is a marker of increased serotonergic activity (35, 
13 
 
36). Similar to LSD in the present study, the hallucinogen psilocybin increased plasma levels of 
cortisol in healthy humans along with increases in prolactin and ACTH (37). Importantly, 
psilocybin (psilocin) activates 5-HT receptors similar to LSD, but does not exhibit relevant 
binding to D1-3 and α1 receptors unlike LSD (34), further supporting the view, that HPA axis 
activation by serotonergic hallucinogens involves mainly 5-HT receptors. Consistently, it has 
been shown that 5-HT2A/C receptors stimulate ACTH and corticosterone release and activate 
CRF-expressing cells in the hypothalamic peraventricular nucleus (38, 39).     
Stimulation of the HPA axis involves serotonin and norepinephrine systems (40). Similar to 
LSD, the serotonin and norepinephrine releaser MDMA increased the plasma concentrations of 
the glucocorticoids cortisol, corticosterone, and 11-dehydrocorticosterone (6). Unlike LSD and 
MDMA, methylphenidate, which activates dopamine and norepinephrine systems but not the 
serotonin system, did not significantly alter plasma steroid levels in humans (6, 41), further 
supporting a role for serotonin receptors in drug-induced HPA axis stimulation. Unexpectedly, 
the glucocorticoid response was more pronounced after LSD administration than after MDMA 
administration (6). This is consistent with the greater psychotropic response to LSD compared 
with MDMA (33); Supplemental Fig. S1A). In contrast, MDMA produced more stimulant-type 
effects, including greater increases in blood pressure and heart rate (33). The greater 
glucocorticoid response after LSD compared with MDMA indicates that the direct serotonergic 
stimulation of postsynaptic 5-HT1 and 5-HT2 receptors by LSD similarly or even more effectively 
stimulated the HPA axis compared with the release of both serotonin and norepinephrine by 
MDMA (42). The relatively similar time course of the glucocorticoid response and psychotropic 
effects of LSD, together with the greater glucocorticoid and psychotropic response to LSD 
compared with MDMA, raise the issue of whether the subjective effects of LSD contribute to or 
further enhance HPA axis stimulation by LSD. We observed a close relationship between LSD-
induced subjective drug effects and changes in plasma corticosterone levels. Associations 
between amphetamine-induced increases in cortisol and subjective arousal and euphoria have 
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been previously reported (15, 41). The covariance of the psychological and endocrine drug 
responses indicates that both are mediated by the same transmitter, likely norepinephrine in the 
case of amphetamine (41) and serotonin in the case of LSD. It is unlikely that glucocorticoids 
critically mediate the psychotropic drug response because the subjective effects of 
methamphetamine (43) and cocaine (44) are unaltered when the drug-induced cortisol response 
is pharmacologically augmented or blocked. On the other hand, the psychotropic effects of LSD 
might have contributed to the endocrine stress response. In fact, the subjective effects occurred 
faster than the cortisol response to LSD. However, only the subjective “good drug effects” and 
“stimulation” induced by LSD and not the “bad drug effects” or “fear” correlated with the steroid 
response over time. Thus, the endocrine changes in response to LSD seem be related to the 
positive and stimulant subjective LSD effects but not to anxiety.    
Both cortisol and prolactin levels increase when the serotonin system is pharmacologically 
activated (35, 36, 45). Interestingly, the prolactin response was greater after MDMA 
administration (33) than after LSD administration (3), whereas the glucocorticoid response was 
less, indicating differential effects of LSD and MDMA on markers of serotonergic activity and 
further supporting the view that the LSD-induced increase in glucocorticoids may have been 
enhanced by the more pronounced subjective effects of LSD. 
A striking difference was found between the plasma concentration-effect curves of LSD in 
the present study and the plasma concentration-effect curves of MDMA in our previous study 
(33). Specifically, the plasma concentration-effect curve of MDMA showed pronounced 
clockwise hysteresis for the psychotropic effects of MDMA (33) and also for the cortisol and 
corticosterone responses (Supplemental Fig. S1A-C), suggesting acute tolerance to the effects 
of MDMA. In contrast, we observed no tolerance to the effects of LSD. This means that the 
effects of LSD on the HPA axis are longer-lasting than those of MDMA, although MDMA has a 
longer plasma half-life than LSD (31, 33). The finding could be explained by the 
pharmacological mechanisms of MDMA and LSD. MDMA releases endogenous serotonin and 
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norepinephrine from presynaptic terminals (42), whereas LSD directly interacts with 
postsynaptic 5-HT receptors (2). In fact, the MDMA-induced cortisol response was blocked after 
duloxetine pretreatment, which prevents MDMA from interacting with the serotonin and 
norepinephrine transporters (46). In the case of cocaine, cocaine-induced euphoria is also 
short-lasting and exhibits acute tolerance (12), similar to MDMA, whereas the cortisol 
concentration-time curve is concordant with the cocaine-plasma concentration time curve (12), 
similar to LSD. 
Unlike LSD, MDMA also increased the mineralocorticoids 11-deoxycorticosterone and 
aldosterone. Mineralocorticoids promote sodium retention and increase extracellular fluid 
volume, thereby increasing blood pressure (25). The MDMA-induced increase in 
mineralocorticoids may thus contribute to the greater increase in blood pressure after MDMA 
administration (33) compared with LSD (3). The mechanisms that underlie the differential effects 
of MDMA and LSD on mineralocorticoid production remain unclear. 
LSD increased DHEA. DHEA is a precursor of many other steroids and may itself modulate 
γ-aminobutyric acid-ergic and glutamatergic neurotransmission (47). DHEA has well-
documented anxiolytic and antidepressant effects (47-50). An interesting line of investigation 
would be to further evaluate the role of DHEA in the potential anxiolytic effects of LSD that are 
reported in terminally ill patients (4).  
Many psychotropic drugs activate the HPA axis (5). Acute administration of serotonin 
transporter inhibitors (35, 51) but not dopamine transporter inhibitors (6, 41, 52) increases 
plasma cortisol levels, indicating that serotonin rather than dopamine mediates HPA axis 
stimulation. Cocaine inhibits presynaptic serotonin, dopamine, and norepinephrine reuptake 
transporters and increases ACTH and cortisol in humans (12, 53). Amphetamine activates the 
norepinephrine and dopamine but not serotonin systems and increases cortisol (15, 41), 
although to a lesser extent than the serotonergic drugs LSD and MDMA. One speculation is that 
16 
 
the stimulant-induced increase in cortisol may depend on dopamine-mediated HPA axis 
stimulation (15, 53). However, the stimulatory effects of amphetamines on ACTH secretion are 
mediated by adrenergic receptors (54) and not by dopamine (40). Additionally, methylphenidate 
activates the dopamine system and produces stimulation and euphoria that are similar to those 
produced by amphetamines (33, 55), but methylphenidate did not increase plasma cortisol 
levels (6, 41) or only to a small extent (55). Furthermore, the MDMA-induced increase in 
circulating cortisol was reduced by pharmacologically blocking the MDMA-induced release of 
serotonin and norepinephrine (42, 46) but not when dopamine release was blocked (52). The 
greater effects of amphetamine on cortisol release compared with methylphenidate are thus 
likely attributable to its greater noradrenergic vs. dopaminergic properties compared with 
methylphenidate (41, 56, 57). Nonetheless, the present study showed that stimulation of the 
serotonin system by LSD increased cortisol levels similarly to MDMA, which has more 
amphetamine-type properties and stimulates both the serotonin and norepinephrine systems.  
The present study has limitations. First, only a single dose and single administration of LSD 
were used. However, a relatively high dose of LSD was administered, which produced 
pronounced psychotropic effects and was within the range of doses used clinically (4) and 
recreationally (1, 2). Additionally, we present LSD exposure-effect relationships that can partially 
substitute for a multiple dose-level study. Second, only psychiatrically and somatically healthy 
subjects with limited previous experience with hallucinogenic drugs were included. LSD may 
differentially affect steroid profiles in chronic LSD or polydrug users. Third, we did not assess 
concentrations of corticotropin-releasing factor or ACTH to describe the drug’s effects on other 
mediators within the HPA axis. 
In conclusion, LSD induced significant effects on plasma glucocorticoids, consistent with 
HPA axis stimulation via serotonergic receptors. Plasma levels of cortisol and particularly 
corticosterone covaried in close relation to the plasma levels of LSD over time. The 
corticosterone response was also closely related to the subjective effects of LSD. The 
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glucocorticoid response to LSD showed no acute pharmacological tolerance, in contrast to the 
response to MDMA. 
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Table 1. Plasma steroid concentrations following LSD or placebo adminstration.
Placebo LSD aF1,15 P value Placebo LSD aF1,15 P value
Glucocorticoids
Cortisol, nM 691±77 1060±40 19.78 <0.001 3545±247 6160±256 45.85 <0.001
Cortisone, nM 58.3±4.2 73.1±4.9 6.17 <0.05 349±23 507±31 25.05 <0.001
Corticosterone, nM 7.43±1.0 38.2±3.6 57.60 <0.001 27.9±2.2 101±9.8 48.66 <0.001
11-Dehydrocorticosterone, nM 4.43±0.7 8.70±0.7 13.97 <0.01 25.7±3.4 39.8±4.4 4.16 NS
Cortisol + Cortisone 737±81 1119±41 18.96 <0.001 3886±260 6666±267 45.86 <0.001
Cortisol/Cortisone ratio 13.9±1.1 20.1±1.3 32.76 <0.001 99.4±7.4 120±7.7 10.89 <0.01
11-Deoxycortisol (precursor of cortisol) , nM 1.67±0.3 2.53±0.5 2.09 NS 13.0±2.0 13.0±3.1 0.00 NS
Corticosterone + 11-Dehydrocorticosterone 11.7±1.6 46.4±4.2 46.00 <0.001 53.6±5.2 141±13.5 27.67 <0.001
Corticosterone/11-Dehydrocorticosterone ratio 2.26±0.3 5.13±0.4 34.11 <0.001 13.4±2.3 21.2±1.5 7.47 <0.05
Mineralocorticoids
Aldosterone, nM 0.42±0.03 0.41±0.04 0.08 NS 3.33±0.1 3.33±0.13 0.00 NS
11-Deoxycorticosterone, nM 0.93±0.16 1.16±0.17 0.50 NS 7.03±1.5 9.94±1.7 0.99 NS
Androgens
DHEA, nM 11.1±1.3 19.1±2.3 12.12 <0.01 71.9±6.8 106±12.1 10.33 <0.01
DHEAS, nM 1761±234 2070±318 1.03 NS 11551±1751 15224±2509 1.94 NS
Androsterone, nM 4.03±0.3 3.59±0.2 1.53 NS 26.3±1.1 27.0±0.9 0.23 NS
Androstendione, nM 3.68±0.5 4.37±0.5 2.03 NS 22.5±2.2 28.8±3.0 8.59 <0.01
Testosterone, nM 10.2±2.3 9.15±2.1 0.80 NS 71.8±17.1 71.3±15.8 0.54 NS
Testosterone in women, nM 2.07±0.4 1.58±0.3 1.30 NS 11.2±1.7 11.9±3.4 0.10 NS
Testosterone in men, nM 18.3±1.9 16.7±1.6 0.44 NS 132.4±14.1 123.3±9.9 0.65 NS
Testosterone/Androstendione ratio 4.50±1.0 3.85±0.9 3.62 NS 31.7±7.1 24.7±5.7 9.43 <0.01
5α-Dihydrotestosterone, nM 1.86±0.3 2.12±0.5 2.40 NS 8.55±1.8 8.03±1.6 0.04 NS
Progestins 
Progesterone, nM 0.22±0.03 0.31±0.05 2.05 NS 1.28±0.1 1.40±0.1 0.36 NS
17α-Hydroxyprogesterone, nM 2.99±0.5 2.96±0.4 0.00 NS 16.8±3.4 15.6±2.6 0.17 NS
Cmax AUC10
Values are mean±SEM in 16 subjects. DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; Cmax, peak plasma 
concentration; AUC10, area under the concentration-time curve up to 10 h. NS, not significant. aF1,7 if only men or women.
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Figure 1. Plasma concentration-time profiles of glucocorticoids and mineralocorticoids following 
LSD or placebo administration. The values, obtained from 16 subjects, are expressed as mean 
± SEM. LSD or placebo was administered at t = 0 h. LSD significantly increased the plasma 
concentrations of the glucocorticoids cortisol (B), cortisone (C), corticosterone (D), and 11-
dehydrocorticosterone (E) compared with placebo. LSD did not alter plasma concentrations of 
the cortisol precursor 11-deoxycortisol (A) or the mineralocorticoids 11-deoxycorticosterone (F) 
and aldosterone (G). 11β-HSD, 11β-hydroxysteroid dehydrogenase; CYP, cytochrome P450. 
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Figure 2. Plasma concentration-time profiles of androgens and progestogens following LSD or 
placebo administration. The values, obtained from 16 subjects (eight per sex for testosterone), 
are expressed as mean ± SEM. LSD or placebo was administered at t = 0 h. LSD significantly 
increased plasma concentrations of dehydroepiandrosterone (DHEA) compared with placebo 
(A). LSD also increased the area under the concentration-time curve
 
but not the maximal 
concentration of androstenedione compared with placebo (C). In contrast, LSD did not alter 
plasma concentrations of dehydroepiandrosterone sulfate (DHEAS) (B) or testosterone (D, F). 
Similarly, LSD did not change plasma levels of the progestogens progesterone (G) and 17α-
hydroxyprogesterone (E). 17β-HSD, 17β-hydroxysteroid dehydrogenase; CYP, cytochrome 
P450. 
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Figure 3. LSD exposure-response relationships. LSD responses are shown as LSD effect (any 
subjective drug effect, cortisol or corticosterone concentration) minus the individual time-
matched effect of placebo. Subjective responses to LSD (A) and LSD-induced changes in 
cortisol (C) and corticosterone (E) over time are presented with the corresponding LSD 
concentrations over time (mean ± SEM) in 16 subjects. LSD or placebo was administered at t = 
0 h. Subjective responses to LSD (B) and LSD-induced changes in cortisol (D) and 
corticosterone (F) concentrations (mean ± SEM) are plotted as a function of mean LSD plasma 
concentrations (hysteresis curves). The time of sampling is noted next to each point (in hours 
after LSD administration). The maximum concentration of LSD was reached 1.7 ± 1 h after LSD 
administration (A, B). The peak psychotropic effect was reached at 2.4 ± 0.8 h, with significant 
alterations in mental state from 0.5 h to > 10 h after LSD administration (A, B) (drug × time 
interaction in the two-way ANOVA: F11,165 = 41.39; P < 0.001). Maximum concentrations of 
cortisol (C, D) and corticosterone (E, F) were reached at 2.5 ± 0.8 h and 1.9 ± 0.5 h (mean ± 
SD), with significant elevations from 1.5 to 6 h and from 1 to 3 h after LSD administration, 
respectively (F11,165 = 17.71; P<0.01 and F11,165 = 13.35, P < 0.001, respectively). 
Counterclockwise hysteresis was observed for any drug effects (B) and cortisol (D), consistent 
with an initial delay between plasma concentration and effect that was attributable to drug 
absorption. Beyond 2 h after LSD administration, the psychotropic effects (A) and changes in 
plasma cortisol levels (C) decreased slowly, in parallel with the plasma levels of LSD, exhibiting 
a close concentration-effect relationship up to 24 h (B, D). LSD significantly increased plasma 
levels of cortisol 1.5-6 h after LSD administration (C). In contrast, plasma levels of 
corticosterone increased more rapidly but fell more quickly back to baseline levels, resulting in 
significant differences in plasma levels 1-3 h after LSD administration and compared with 
placebo (E). There was no evidence of acute pharmacological tolerance (clockwise hysteresis) 
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for any of the effects of LSD. After drug administration, subjective drug effects increased 
together with plasma levels of corticosterone but more rapidly than plasma levels of cortisol (G, 
H). *P < 0.05 and ***P < 0.001, compared with the time-matched placebo concentration (Tukey 
tests based on significant drug × time interactions in the two-way ANOVAs. 
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Supplemental methods: 
1. Quantification of steroid hormones in human plasma samples 
1.1. Chemicals and reagents 
UPLC-grade purity methanol, acetonitrile and formic acid were purchased from Sigma-Aldrich 
(St. Louis, MO) or Biosolve (Dieuze, France). Distilled water was deionized using a MilliQ water 
purification system (Millipore, USA). Aldosterone, 11-deoxycorticosterone, corticosterone, 
dehydroepiandrosterone-3-sulfate, androstenedione, testosterone and [2,2,4,6,6,21,21-2H7]-
aldosterone (98% isotopic purity) were purchased from Sigma-Aldrich (St. Louis, MO). 11-
Dehydrocorticosterone, dehydroepiandrosterone (DHEA), 5α-dihydrotestosterone, 
androsterone, progesterone, 17α-hydroxyprogesterone, 11-deoxycortisol, cortisol, cortisone, 
[16,16-2H2]-androsterone (98% isotopic purity) and [16,16,17-2H3]-5α-dihydrotestosterone (98% 
isotopic purity) were purchased from Steraloids (Newport, RI). [1,2-2H2]-Testosterone (98% 
isotopic purity), [2,2,4,6,6,16,16-2H7]-4-androsten-3,17-Dione (98% isotopic purity) and 
[2,2,4,6,6,17α,21,21-2H8]-corticosterone (98% isotopic purity) were purchased from C/D/N 
Isotopes Inc. (Pointe-Claire, Canada). All other chemicals were purchased from Sigma-Aldrich 
(St. Louis, MO) and of the highest grade available. 
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1.2. Instrumentation and analytical conditions 
Analytical instruments: All analytes were measured simultaneously by ultra-pressure liquid 
chromatography-tandem mass spectrometry (UPLC-MS/MS) using a Agilent 1290 UPLC 
instrument equipped with a binary solvent delivery system, an auto sampler (at 4 °C ), and a 
column oven, coupled to an Agilent 6490 triple quadrupole mass spectrometer equipped with a 
jet stream electrospray ionization interface (AJS-ESI) (Agilent Technologies, Basel, 
Switzerland).  
Liquid chromatography: The chromatographic separation of the analytes was achieved using a 
Waters ACQUITY UPLC BEH C18, 1.7 µm, 2.1×150 mm, column (Waters, Wexford, Ireland). 
The column temperature was maintained at 65 ºC. Steroids were separated using a mobile 
phase consisting of water-acetonitrile-formic acid (A) (95/5/0.1; v/v/v) and (B) (5/95/0.1; v/v/v). 
The injection volume was 5 µL per sample. Methanol in water (50/50 v/v) was used as needle 
and needle-seat flushing solvent for 10 s after sample aspiration. Samples were stored until 
analysis in the auto sampler (maintained at 4 °C). Method A: Aldosterone, corticosterone, 11-
dehydrocorticosterone, cortisol, cortisone, DHEA, DHEA-3-sulfate, progesterone, 17α-
hydroxyprogesterone, 11-deoxycortisol, 11-deoxycorticosterone, aldosterone-d7, and 
corticosterone-d8 were eluted by the gradient 25 - 70% of mobile phase B during 0 - 10 min, 
and 100% of mobile phase B at 10.1 min onwards at a constant flow rate of 0.63 mL/min. The 
run was stopped after 12.0 min, followed by re-equilibration of the column for 2 min. Method B: 
Androsterone, testosterone, androstenedione, 5α-dihydrotestosterone, androsterone-d2, 
testosterone-d2, androstenedione-d7, and 5α-dihydrotestosterone-d3 were eluted by the 
gradient of 25 – 59% of mobile phase B during 0 - 20 min at a gradient flow rate from 0.65 
mL/min to 0.36 mL/min, and 100% of mobile phase B at 22 min onwards at a constant flow rate 
of 0.65 mL/min. The run was stopped at 24 min, followed by re-equilibration of the column for 1 
min. 
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Mass spectrometry: The AJS-ESI source was operated with nitrogen as drying and collision gas 
in the positive ion mode for all analytes, except for aldosterone and aldosterone-d7, which were 
analyzed using negative ionization. The ion source conditions were identified and optimized for 
all individual analytes using the source optimization software module (Agilent Technologies, 
California, USA, B.07.01) (Supplemental Table S1). Analytes were monitored by multiple 
reaction-monitoring (MRM) and characteristic precursor ions and corresponding transitions for 
quantifier- and qualifier-ions were automated defined by the use of the compound optimizer 
software module included within the Mass Hunter Workstation software (Agilent Technologies, 
California, USA) (Supplemental Table S2). 
Data analysis: Data acquisition and subsequent data analysis was performed using Mass 
Hunter Workstation Acquisition software Version 07.01 SP1 and MassHunter Workstation 
Software Quantitative Analysis Version B.07.00 /Build 7.0457.0, respectively (Agilent 
Technologies, California, USA). 
Sample extraction: Sample extraction was performed using a vacuum manifold (Agilent 
Technologies, California, USA) equipped with Oasis HBL SPE cartridges (Waters, 
Massachusetts; USA, Lot No. 116B32307A). Samples were evaporated to dryness using a 
Genevac EZ-2 plus centrifugal vacuum evaporator (Genevac, Suffolk, UK).  
Standard solutions: Stock solutions of analytes and deuterium internal standards (I.S.) were 
prepared by weighing pure compounds on an analytical balance (Mettler-Toledo, Switzerland) 
and dissolving in methanol to obtain a concentration of 10 mM for analytes and I.S. The 
standard solutions of analytes and I.S. were freshly prepared in methanol by further diluting the 
corresponding stock solution to obtain a concentration of 100 µM. All stock solutions of 
standards and I.S. were stored at -20 ºC. 
Sample preparation: For solid phase extraction each sample, calibrator or quality control (QC) 
(700 µL) was mixed with protein precipitation solution (100 µL, zinc sulfate 0.8 M in 
water/methanol (50/50 v/v)) containing I.S. and diluted to a final volume of 1 mL with water. The 
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samples were incubated for 10 min in a thermoshaker with thorough shaking (1300 rpm, 4 °C) 
and centrifuged (10 min, 16,000 × rcf, 4 °C). Supernatants (700 µL) were transferred to Oasis 
HBL SPE cartridges (preconditioned with methanol and water, 1 mL each). Following one wash 
with water (1 mL) and two washes with methanol/water (1 mL, 10/90 v/v), the samples were 
eluted with methanol (1 mL) and evaporated to dryness. The samples were reconstituted in 25 
µL methanol (10 min, 1300 rpm, 4 °C, thermoshaker) and transferred into new glass vials. 
Chromatographic performance: Ten point calibration curves were generated by a zero sample 
(charcoal treated human plasma/water mixture containing I.S.) and nine calibrators 
(Supplemental Table S3). To meet requirements of the FDA guidance for industry, the 
coefficient of determination (R2) has to be higher than 0.96 and at least 75% of all calibrators 
have to be valid (Supplemental Table S3).  
Specificity: Blank samples without the addition of analyte and I.S. were processed and injected 
into the UPLC–MS/MS within an analytical run. The peak areas evaluated in the blank samples 
were not allowed to exceed 20% of the mean LLOQ peak area. 
Recovery: The absolute recovery was determined by comparing the mean peak areas for 
extracted with unextracted samples (100% recovery) at the concentrations of QC high, QC 
medium, and QC low (Supplemental Table S4).  
Limit of detection (LLOD) and limit of quantification (LLOQ): Lower limit of detection (LLOD) and 
lower limit of quantification (LLOQ) were determined by direct injection of decreasing amounts 
of analyte and were calculated as the concentration giving peaks with a signal-to-noise ratio of ≥ 
3 and ≥ 5, respectively. The LLOQ was decided as the lowest concentration on the calibration 
curve which fulfilled the criteria of imprecision ±15%, and inaccuracy within ±15% 
(Supplemental Table S3). 
Reproducibility: Five replicates of QCs at three concentration levels (QC high, QC medium, and 
QC low) were processed and injected into the UPLC–MS/MS. To ensure the reproducibility, 
these sets of QCs were tested within validation runs. In each run, intra-run imprecision (% 
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coefficient of variation; CV%) of each QC series had to be below 15% (20% at the LLOQ) and 
intra-run inaccuracy (% relative error of measurement; RE%) had to be within ±15% of the 
nominal values (±20% at the LLOQ) (Supplemental Table S5). 
Carry-over: To evaluate the carry-over of all analytes and I.S. in each analytical run blank 
samples were injected immediately after the highest calibrator upper limit of quantification 
(ULOQ). Mean carry-over in the blank sample following the ULOQ had not to exceed 20% of the 
signal of the LLOQ for analyte and 5% for I.S.  
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Supplemental Table S1 Optimized ion source conditions and analytical parameters. 
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11-Dehydrocorticosterone 290 14 20 300 11 3000 1500 200 110 150 60 
11-Deoxycorticosterone 290 14 20 300 11 3000 1500 200 110 150 60 
11-Deoxycortisol 290 14 20 300 11 3000 1500 200 110 150 60 
17α-Hydroxyprogesterone 290 14 20 300 11 3000 1500 200 110 150 60 
5α-Dihydrotestosterone /  
5α-Dihydrotestosterone-d3 
290 20 15 350 11 3000 1500 120 90 150 60 
Aldosterone /  
Aldosterone-d7 
290 14 20 300 11 3000 1500 200 110 150 60 
Androstendione / Androstendione-d7 290 20 15 350 11 2000 1500 170 90 150 60 
Androsterone /  
Androsterone-d2 
290 20 15 350 11 2000 1500 170 90 150 60 
Corticosterone / Corticosterone-d8 290 14 20 300 11 3000 1500 200 110 150 60 
Cortisol 290 14 20 300 11 3000 1500 200 110 150 60 
Cortisone /  
Cortisone-d2 
290 14 20 300 11 3000 1500 200 110 150 60 
Dehydroepiandrosterone 290 14 20 300 11 3000 1500 200 110 150 60 
Dehydroepiandrosterone-3-sulfate 290 14 20 300 11 3000 1500 200 110 150 60 
Progesterone 290 14 20 300 11 3000 1500 200 110 150 60 
Testosterone /  
Testosterone-d2 
290 20 25 350 11 2500 1500 170 90 150 60 
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Supplemental Table S2 Multiple reaction monitoring (MRM) analyte transitions. 
Analyte 
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11-Dehydrocorticosterone A 345.2 121 54.9 21; 57 positive 100 Corticosterone-d8 
11-Deoxycorticosterone A 331.2 97.1 109 28; 25 positive 100 Corticosterone-d8 
11-Deoxycortisol A 347.2 97 109 32; 24 positive 100 Corticosterone-d8 
17α-Hydroxyprogesterone A 331.2 97 109 32; 28 positive 100 Corticosterone-d8 
5α-Dihydrotestosterone B 291.2 159 255 24; 12 positive 100 5α-Dihydrotestosterone-d3 
5α-Dihydrotestosterone-d3 B 294.3 163 258 24; 12 positive 100   
Aldosterone A 359.2 331 189 17; 24 negative 400 Aldosterone-d7 
Aldosterone-d7 A 366.2 338 196 17; 24 negative 200   
Androstenedione B 287.2 97.1 109 24; 20 positive 100 Androstenedione-d7 
Androstenedione-d7 B 294.3 100 113 24; 28 positive 100   
Androsterone B 273.2 147 255 24 ;12 positive 200 Androsterone-d2 
Androsterone-d2 B 275.2 118 257 52; 8 positive 100   
Corticosterone A 347.2 121 329 25; 9 positive 100 Corticosterone-d8 
Corticosterone-d8  A 355.2 125 337 25; 12 positive 100   
Cortisol A 363.2 121 105 36; 56 positive 100 Cortisone-d2 
Cortisone A 361.2 121 163 36; 24 positive 100 Cortisone-d2 
Cortisone-d2 A 363.2 123 165 36; 24 positive 100   
Dehydroepiandrosterone A 271.2 253 213 6; 12 positive 100 Androstenedione-d7 
Dehydroepiandrosterone-3-sulfate A 271.1 253 213 6; 10 positive 200 Corticosterone-d8 
Progesterone A 315.2 109 97.1 20; 24 positive 50 Corticosterone-d8 
Testosterone B 289.2 97.1 109 28; 32 positive 50 Testosterone-d2 
Testosterone-d2 B 291.5 111 125 13; 24 positive 50   
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Supplemental Table S3 Limit of detection (LLOD), lower limit of quantification (LLOQ), signal-to-
noise ratio (S/N), retention time (RT), linearity, and calibration range. 
Analyte LLOD 
(nM) 
LLOQ 
(nM) 
(S/N) RT 
(min) 
Linearity 
(R2) 
Calibration range 
(nM) 
11-Dehydrocorticosterone 0.49 0.98 10.5 3.1 0.998 0.98-250 
11-Deoxycorticosterone 0.39 0.78 13.7 5.1 0.998 0.78-200 
11-Deoxycortisol 0.39 0.78 9.9 3.73 0.992 0.78-200 
17α-Hydroxyprogesterone 0.39 0.78 10.5 5.59 0.998 0.78-200 
5α-Dihydrotestosterone 0.49 0.98 60.7 11.9 0.999 0.98-250 
Aldosterone 0.10 0.2 12.0 1.72 0.999 0.2-50 
Androstenedione 0.39 0.78 13.8 8.85 0.999 0.78-200 
Androsterone 1.96 3.91 5.6 16.2 0.999 1.95-500 
Corticosterone 0.49 0.98 54.1 3.56 0.996 0.98-250 
Cortisol 0.98 1.95 5.7 2.29 0.991 3.91-1000 
Cortisone 0.98 1.95 38.0 2.24 0.994 1.95-500 
Dehydroepiandrosterone 1.96 3.91 7.3 5.37 0.999 1.95-500 
Dehydroepiandrosterone 3-sulfate 9.77 19.53 9.1 3.55 0.993 19.53-5000 
Progesterone 0.03 0.05 7.6 7.4 0.994 0.39-100 
Testosterone 0.20 0.39 55.3 7.6 0.999 0.39-100 
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Supplemental Table S4 Recovery (QC high, QC medium, QC low). 
  
Nominal  
concentration (nM) 
Recovery (%) CV% 
  
QC 
high 
QC 
medium 
QC 
low 
QC 
high 
QC 
medium 
QC 
low 
QC 
high 
QC 
medium 
QC 
low 
11-Dehydrocorticosterone 125 31.3 2.0 114.0 103.2 95.9 3.7 2.1 2.2 
11-Deoxycorticosterone 100 25.0 1.6 98.5 95.4 90.4 8.9 3.1 3.3 
11-Deoxycortisol 100 25.0 1.6 106.7 91.8 95.0 6.7 2.9 3.4 
17α-
Hydroxyprogesterone 
100 25.0 1.6 82.7 83.5 81.8 9.3 4.4 1.4 
5α-Dihydrotestosterone 125 31.3 2.0 88.7 120.2 96.6 20.0 15.3 13.9 
Aldosterone 25 6.3 0.4 99.2 99.1 98.3 5.2 4.6 10.3 
Androstenedione 100 25.0 1.6 100.2 100.7 98.0 1.8 2.4 3.5 
Androsterone 250 62.5 3.9 94.9 98.4 102.5 1.7 5.8 0.2 
Corticosterone 125 31.3 2.0 111.4 98.9 95.1 5.6 2.0 2.2 
Cortisol 250 62.5 3.9 108.0 102.9 97.4 3.5 4.5 2.2 
Cortisone 250 62.5 3.9 100.2 104.5 98.5 4.9 5.1 1.6 
Dehydroepiandrosterone 250 62.5 3.9 102.1 102.7 107.8 5.4 4.3 5.7 
Dehydroepiandrosterone-
3-sulfate 
2500 625.0 39.1 88.9 103.8 96.8 5.6 4.1 2.6 
Progesterone 50 12.5 0.8 80.9 92.4 98.0 11.4 6.0 0.8 
Testosterone 50 12.5 0.8 101.7 103.9 100.5 3.9 1.5 2.2 
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Supplemental Table S5 Reproducibility: Nominal and measured concentration, standard deviation (S.D.), imprecision (CV%), and 
inaccuracy (RE%) of QC high, QC medium, and QC low.  
  Nominal  
concentration (nM) 
Measured  
concentration (nM) 
S.D. CV% RE% 
Analyte QC  
high 
QC  
med 
QC  
low 
QC  
high 
QC  
med 
QC  
low 
QC  
high 
QC  
med 
QC  
low 
QC  
high 
QC  
med 
QC  
low 
QC  
high 
QC  
med 
QC  
low 
11-Dehydrocorticosterone 125 31.3 2.0 120.7 28.6 1.8 9.9 1.0 0.1 8.2 3.4 7.0 -3.5 -8.5 -6.8 
11-Deoxycorticosterone 100 25.0 1.6 101.6 25.3 1.7 5.3 0.6 0.1 5.2 2.2 8.2 1.6 1.1 5.8 
11-Deoxycortisol 100 25.0 1.6 96.5 24.2 1.5 8.1 0.5 0.1 8.4 1.9 3.6 -3.5 -3.2 -1.8 
17α-Hydroxyprogesterone 100 25.0 1.6 102.9 26.0 1.4 9.4 0.7 0.1 9.2 2.9 8.6 2.9 3.9 -12.4 
5α-Dihydrotestosterone 125 31.3 2.0 123.8 30.2 1.8 2.9 0.5 0.1 2.4 1.7 3.7 -0.9 -3.4 -5.3 
Aldosterone 25 6.3 0.4 23.5 5.5 0.3 1.9 0.5 0.0 8.0 8.4 10.7 -6.0 -11.6 -13.1 
Androstenedione 100 25.0 1.6 98.9 24.3 1.4 1.7 0.9 0.0 1.7 3.7 1.0 -1.1 -2.8 -9.7 
Androsterone 250 62.5 3.9 250.8 58.9 4.1 4.5 1.0 0.1 1.8 1.7 2.3 0.3 -5.8 4.5 
Corticosterone 125 31.3 2.0 122.6 31.3 1.8 9.2 0.8 0.1 7.5 2.5 8.1 -1.9 0.0 -7.6 
Cortisol 250 62.5 3.9 240.7 63.7 4.5 19.1 1.1 0.3 7.9 1.7 7.7 -3.7 2.0 13.9 
Cortisone 250 62.5 3.9 243.5 63.9 3.4 11.5 2.3 0.3 4.7 3.5 9.4 -2.6 2.2 -13.5 
Dehydroepiandrosterone 250 62.5 3.9 236.6 53.5 3.7 19.3 3.0 0.4 8.2 5.7 11.4 -5.4 -14.3 -5.9 
Dehydroepiandrosterone-
3-sulfate 
2500 625.0 39.1 2643.0 685.2 42.0 5.8 38.7 6.1 0.2 5.7 14.6 5.7 9.6 7.4 
Progesterone 50 12.5 0.8 49.2 11.2 0.7 3.2 0.2 0.0 6.5 2.1 4.2 -1.5 -10.7 -11.2 
Testosterone 50 12.5 0.8 43.8 12.3 0.7 1.5 0.5 0.0 3.4 4.0 6.5 -12.3 -1.5 -13.4 
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Figure S1 
 Strajhar et al. 
 
 
 
 
 
 
 
44
Supplemental Figure S1 MDMA exposure-response relationship. MDMA responses are 
shown as MDMA effect (any subjective drug effect, cortisol or corticosterone concentration) 
minus the individual time-matched effect of placebo. MDMA or placebo was administered at t 
= 0 h. Subjective responses to MDMA (A) and MDMA-induced changes in cortisol (B) and 
corticosterone (C) concentrations (mean ± SEM) of 16 subjects are plotted against mean 
MDMA plasma concentrations (hysteresis curves). The time of sampling is noted next to 
each point (in hours after MDMA administration). Clockwise hysteresis was observed for any 
drug effects (A), cortisol (B), and corticosterone (C) consistent with acute tolerance to the 
effects of MDMA. After drug administration, the subjective drug effects increased faster and 
in particular decreased faster than the plasma levels of cortisol (D) or corticosterone (E) over 
time (clockwise hysteresis). Thus, over time MDMA-induced changes in glucocorticoids do 
not well reflect the psychotropic effects of the drug in contrast to LSD. 
 
